Clinical trial
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII…
NCT00189982 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00189982 |
|---|---|
| Title | Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 |
| Official title | Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With Severe to Moderately Severe Hemophilia A - A Continuation of Baxter Clinical Study 060101 |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM) |
| Enrollment | 4 |
| Start date | Dec 17, 2004 |
| Primary completion | Nov 10, 2006 |
| Completion | Nov 10, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | May 5, 2021 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: